About Pachytene checkpoint protein 2 homolog
Pachytene checkpoint protein 2 homolog (TRIP13) is a protein
from Homo sapiens identified by UniProt accession
Q15645, 432 residues long.
MolForge cross-references it against 0 known binders and
259 disease associations.
Target properties
| Protein name | Pachytene checkpoint protein 2 homolog |
| UniProt accession | Q15645 |
| Gene | TRIP13 |
| Organism | Homo sapiens |
| Length | 432 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (259)
Diseases linked to this target (Open Targets).
- oocyte maturation defect 9 · score 0.68
- mosaic variegated aneuploidy syndrome · score 0.65
- neurodegenerative disease · score 0.55
- Nephroblastoma · score 0.37
- lysosomal storage disease · score 0.37
- Red cell distribution width · score 0.12
- hepatocellular carcinoma · score 0.12
- neoplasm · score 0.11
- glioblastoma multiforme · score 0.10
- non-small cell lung carcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15645-F1 | alphafold | PREDICTED | 86.70 | — |
Amino-acid sequence (432 residues)
MDEAVGDLKQ ALPCVAESPT VHVEVHQRGS STAKKEDINL SVRKLLNRHN IVFGDYTWTE FDEPFLTRNV QSVSIIDTEL KVKDSQPIDL SACTVALHIF QLNEDGPSSE NLEEETENII AANHWVLPAA EFHGLWDSLV YDVEVKSHLL DYVMTTLLFS DKNVNSNLIT WNRVVLLHGP PGTGKTSLCK ALAQKLTIRL SSRYRYGQLI EINSHSLFSK WFSESGKLVT KMFQKIQDLI DDKDALVFVL IDEVESLTAA RNACRAGTEP SDAIRVVNAV LTQIDQIKRH SNVVILTTSN ITEKIDVAFV DRADIKQYIG PPSAAAIFKI YLSCLEELMK CQIIYPRQQL LTLRELEMIG FIENNVSKLS LLLNDISRKS EGLSGRVLRK LPFLAHALYV QAPTVTIEGF LQALSLAVDK QFEERKKLAA YI
Explore Pachytene checkpoint protein 2 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets